|
EP3409278B8
(en)
|
2011-07-21 |
2020-11-04 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
RS57559B1
(sr)
|
2013-09-06 |
2018-10-31 |
Aurigene Discovery Tech Ltd |
1,3,4-oksadiazol i 1,3,4-tiadiazol derivativi kao imunomodulatori
|
|
HRP20181052T1
(hr)
|
2013-09-06 |
2018-09-07 |
Aurigene Discovery Technologies Limited |
Derivati 1,2,4-oksadiazola kao imunomodulatori
|
|
KR20160075506A
(ko)
|
2013-09-06 |
2016-06-29 |
오리진 디스커버리 테크놀로지스 리미티드 |
면역조절제로서 사이클릭 펩티도미메틱 화합물
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
ES2770684T3
(es)
|
2014-03-14 |
2020-07-02 |
Novartis Ag |
Moléculas de anticuerpos contra LAG-3 y usos de los mismos
|
|
CN106460070B
(zh)
|
2014-04-21 |
2021-10-08 |
纳特拉公司 |
检测染色体片段中的突变和倍性
|
|
HRP20210458T1
(hr)
|
2014-06-12 |
2021-05-14 |
Universidade Do Porto - Reitoria |
Cjepivo za imunološki kompromitirane domaćine
|
|
KR102130600B1
(ko)
*
|
2014-07-03 |
2020-07-08 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
CA2955788C
(en)
|
2014-07-22 |
2024-01-16 |
Ziyong Sun |
Anti-pd-1 antibodies
|
|
SG10201901057UA
(en)
|
2014-08-05 |
2019-03-28 |
Cb Therapeutics Inc |
Anti-pd-l1 antibodies
|
|
RU2718914C2
(ru)
|
2014-09-13 |
2020-04-15 |
Новартис Аг |
Сочетанные способы лечения с использованием ингибиторов alk
|
|
US9988452B2
(en)
*
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
|
MX382902B
(es)
|
2014-10-31 |
2025-03-13 |
Oncomed Pharm Inc |
Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
MX2017006918A
(es)
|
2014-11-26 |
2018-01-25 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cd38.
|
|
CN110894240B
(zh)
|
2014-11-26 |
2022-04-15 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
KR20170090506A
(ko)
*
|
2014-12-19 |
2017-08-07 |
다나-파버 캔서 인스티튜트 인크. |
키메라 항원 수용체 및 이의 사용 방법
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
CA2979137C
(en)
|
2015-03-10 |
2023-12-19 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
SG11201707383PA
(en)
|
2015-03-13 |
2017-10-30 |
Cytomx Therapeutics Inc |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
|
JP6936784B2
(ja)
*
|
2015-03-30 |
2021-09-22 |
エスティーキューブ，インコーポレイテッド |
グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法
|
|
US11933786B2
(en)
|
2015-03-30 |
2024-03-19 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-L1 and methods of use thereof
|
|
PT3298021T
(pt)
|
2015-05-18 |
2019-08-05 |
Tolero Pharmaceuticals Inc |
Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada
|
|
HRP20201031T1
(hr)
|
2015-05-29 |
2020-10-16 |
Agenus Inc. |
Anti-ctla-4 protutijela i postupci njihove upotrebe
|
|
EP3307777A4
(en)
*
|
2015-06-11 |
2019-02-13 |
Wuxi Biologics (Shanghai) Co. Ltd. |
NOVEL ANTI-PD-L1 ANTIBODIES
|
|
WO2017020291A1
(en)
*
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
ES2839212T3
(es)
|
2015-09-29 |
2021-07-05 |
Inst Nat Sante Rech Med |
Métodos para determinar el estado metabólico de linfomas B
|
|
EP3378871A4
(en)
|
2015-11-17 |
2019-08-07 |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF
|
|
ES2913208T3
(es)
|
2015-12-01 |
2022-06-01 |
Glaxosmithkline Ip Dev Ltd |
Tratamientos de combinación y usos y métodos de los mismos
|
|
US10858432B2
(en)
|
2015-12-02 |
2020-12-08 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-1 and methods of use thereof
|
|
RU2020113165A
(ru)
|
2015-12-03 |
2020-06-09 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Циклические пуриновые динуклеотиды в качестве модуляторов sting
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
CN106939047B
(zh)
*
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
|
WO2017118634A1
(en)
|
2016-01-04 |
2017-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
|
WO2017122203A1
(en)
|
2016-01-11 |
2017-07-20 |
Technion Research & Development Foundation Limited |
Methods of determining prognosis of sepsis and treating same
|
|
CA3013051A1
(en)
|
2016-01-29 |
2017-08-03 |
Heyue Zhou |
Antigen binding proteins that bind pd-l1
|
|
WO2017148424A1
(zh)
*
|
2016-03-04 |
2017-09-08 |
四川科伦博泰生物医药股份有限公司 |
一种pdl-1抗体、其药物组合物及其用途
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
WO2017161976A1
(en)
*
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
|
CN109071636A
(zh)
|
2016-03-29 |
2018-12-21 |
斯特库比股份有限公司 |
用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法
|
|
US11660352B2
(en)
|
2016-03-29 |
2023-05-30 |
Stcube, Inc. |
Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
|
|
HUE058932T2
(hu)
|
2016-04-07 |
2022-09-28 |
Glaxosmithkline Ip Dev Ltd |
Fehérjemodulátorokként hasznos heterociklikus amidok
|
|
MX2018012266A
(es)
|
2016-04-07 |
2019-05-30 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterociclicas como moduladores de proteinas.
|
|
US10604531B2
(en)
|
2016-05-05 |
2020-03-31 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
CN105968200B
(zh)
*
|
2016-05-20 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-l1人源化单克隆抗体及其应用
|
|
CN106008714B
(zh)
|
2016-05-24 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-1人源化单克隆抗体及其应用
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
AU2017279029A1
(en)
|
2016-06-08 |
2018-12-20 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as ATF4 pathway inhibitors
|
|
WO2017212423A1
(en)
|
2016-06-08 |
2017-12-14 |
Glaxosmithkline Intellectual Property Development Limited |
Chemcical compounds
|
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
TW201803905A
(zh)
|
2016-06-20 |
2018-02-01 |
克馬伯有限公司 |
用於免疫腫瘤學之多重專一性抗體
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
EP4050032A1
(en)
|
2016-06-28 |
2022-08-31 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
IL276515B2
(en)
*
|
2016-06-29 |
2025-11-01 |
Checkpoint Therapeutics Inc |
Pd-l1-specific antibodies and methods of using the same
|
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
|
CA3031047A1
(en)
|
2016-07-20 |
2018-01-25 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
|
KR20190031299A
(ko)
|
2016-07-20 |
2019-03-25 |
주식회사 에스티큐브 |
글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
|
|
CN106243223B
(zh)
*
|
2016-07-28 |
2019-03-05 |
北京百特美博生物科技有限公司 |
抗人pdl1抗体及其用途
|
|
CN109562282A
(zh)
*
|
2016-07-29 |
2019-04-02 |
伊莱利利公司 |
用于治疗癌症的使用merestinib和抗-pd-l1或抗-pd-1抑制剂的组合疗法
|
|
KR102604433B1
(ko)
|
2016-08-09 |
2023-11-24 |
키맵 리미티드 |
항-icos 항체
|
|
FI3500299T3
(fi)
|
2016-08-19 |
2024-02-14 |
Beigene Switzerland Gmbh |
Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa
|
|
JP2019526595A
(ja)
|
2016-09-09 |
2019-09-19 |
ティージー セラピューティクス，インコーポレイテッド |
血液癌を治療するための抗ｃｄ２０抗体、ｐｉ３キナーゼ−デルタ阻害剤および抗ｐｄ−１抗体または抗ｐｄ−ｌ１抗体の組み合わせ
|
|
MX2019003683A
(es)
|
2016-10-11 |
2019-08-22 |
Agenus Inc |
Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
|
|
WO2018071913A2
(en)
|
2016-10-14 |
2018-04-19 |
Dana-Farber Cancer Institute, Inc. |
Modular tetrameric bispecific antibody platform
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
CN106496327B
(zh)
*
|
2016-11-18 |
2019-01-15 |
昆山百尔泰生物科技有限公司 |
针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体
|
|
JP2020511407A
(ja)
|
2016-12-01 |
2020-04-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
併用療法
|
|
EP3548069A1
(en)
|
2016-12-01 |
2019-10-09 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
|
AU2017373945B2
(en)
|
2016-12-07 |
2025-01-23 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
AU2017373944B2
(en)
|
2016-12-07 |
2022-02-03 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
JP7104703B2
(ja)
|
2016-12-14 |
2022-07-21 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン
|
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
|
JP2020503883A
(ja)
|
2017-01-13 |
2020-02-06 |
アジェナス インコーポレイテッド |
Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
CN106699891B
(zh)
*
|
2017-01-25 |
2019-04-09 |
北京天广实生物技术股份有限公司 |
一种抗pd-l1抗体、其药物组合物及其用途
|
|
KR102585848B1
(ko)
|
2017-02-24 |
2023-10-11 |
마크로제닉스, 인크. |
Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도
|
|
US20200062735A1
(en)
|
2017-02-27 |
2020-02-27 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors
|
|
EP3592769B1
(en)
*
|
2017-03-09 |
2024-05-08 |
Genmab A/S |
Antibodies against pd-l1
|
|
EP3600427A1
(en)
|
2017-03-24 |
2020-02-05 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
JOP20190222A1
(ar)
*
|
2017-04-11 |
2019-09-24 |
Zymeworks Inc |
الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
|
|
WO2018191502A2
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
|
CN110770345A
(zh)
|
2017-04-14 |
2020-02-07 |
托尔奈公司 |
免疫调节多核苷酸、抗体缀合物及其使用方法
|
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
WO2018204363A1
(en)
|
2017-05-01 |
2018-11-08 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
EP3630148A4
(en)
*
|
2017-05-26 |
2021-06-16 |
The Johns Hopkins University |
MULTIFUNCTIONAL ANTIBODY LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE
|
|
EP3630838A1
(en)
|
2017-06-01 |
2020-04-08 |
CytomX Therapeutics, Inc. |
Activatable anti-pdl1 antibodies, and methods of use thereof
|
|
BR112019025612A2
(pt)
|
2017-06-05 |
2020-06-16 |
Janssen Biotech, Inc. |
Métodos de manipular carga de superfície para a produção de anticorpos biespecíficos
|
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
CA3066048A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
TW201904993A
(zh)
|
2017-06-22 |
2019-02-01 |
瑞士商諾華公司 |
IL-1β 結合抗體之用途
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
CA3066774A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US11597768B2
(en)
|
2017-06-26 |
2023-03-07 |
Beigene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
|
JP2020525513A
(ja)
|
2017-07-03 |
2020-08-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物
|
|
JP2020525512A
(ja)
|
2017-07-03 |
2020-08-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物
|
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
WO2019046856A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF
|
|
TW201922721A
(zh)
|
2017-09-07 |
2019-06-16 |
英商葛蘭素史克智慧財產發展有限公司 |
化學化合物
|
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
WO2019069269A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
INTERFERON GENE STIMULATOR MODULATORS USEFUL IN THE TREATMENT OF HIV
|
|
WO2019069270A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
|
|
IL273896B2
(en)
|
2017-10-11 |
2025-08-01 |
Aurigene Oncology Ltd |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
DE102017125019B4
(de)
*
|
2017-10-25 |
2019-10-17 |
Epiontis Gmbh |
PDCD1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere PD1+ Zellen
|
|
MX2020004531A
(es)
|
2017-11-03 |
2020-08-03 |
Aurigene Discovery Tech Ltd |
Inhibidores dobles de tim-3 y las vias de pd-1.
|
|
EA202090749A1
(ru)
|
2017-11-06 |
2020-08-19 |
Ориджен Дискавери Текнолоджис Лимитед |
Способы совместной терапии для иммуномодуляции
|
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
|
RU2020121458A
(ru)
|
2017-11-30 |
2021-12-30 |
Новартис Аг |
Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
|
|
CN107973854B
(zh)
*
|
2017-12-11 |
2021-05-04 |
苏州银河生物医药有限公司 |
Pdl1单克隆抗体及其应用
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
KR102311838B1
(ko)
*
|
2017-12-27 |
2021-10-14 |
주식회사 파멥신 |
항-pd-l1 항체 및 이의 용도
|
|
WO2019134946A1
(en)
|
2018-01-04 |
2019-07-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
MX2020007406A
(es)
|
2018-01-10 |
2020-09-14 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
|
|
US11673897B2
(en)
|
2018-01-26 |
2023-06-13 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
CR20250117A
(es)
|
2018-01-26 |
2025-05-09 |
Exelixis Inc |
COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355)
|
|
HRP20251184T1
(hr)
|
2018-01-26 |
2025-12-05 |
Exelixis, Inc. |
Spojevi za liječenje poremećaja ovisnih o kinazi
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
EP3756012A1
(en)
|
2018-02-21 |
2020-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
|
JP2021518104A
(ja)
|
2018-03-14 |
2021-08-02 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
|
IL297847B2
(en)
*
|
2018-04-09 |
2024-02-01 |
Origincell Therapeutics Co Ltd |
Anti-PD-L1 antibody and its use
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
WO2019210055A2
(en)
|
2018-04-26 |
2019-10-31 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CA3098420A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Binding molecules against bcma and uses thereof
|
|
CN112424167A
(zh)
|
2018-07-09 |
2021-02-26 |
葛兰素史密斯克莱知识产权发展有限公司 |
化学化合物
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CA3103385A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
|
US20210324081A1
(en)
|
2018-10-22 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
BR112021009411A2
(pt)
|
2018-11-16 |
2021-08-17 |
Arqule, Inc. |
combinação farmacêutica para tratamento de câncer
|
|
WO2020104496A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
|
CA3121140A1
(en)
|
2018-11-30 |
2020-06-04 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in hiv therapy
|
|
KR20210099066A
(ko)
|
2018-12-04 |
2021-08-11 |
스미토모 다이니폰 파마 온콜로지, 인크. |
암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
|
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
|
IL283860B2
(en)
|
2018-12-13 |
2025-10-01 |
Exelixis Inc |
Crystalline forms and salt forms of kinase inhibitor
|
|
EP3898699A1
(en)
|
2018-12-19 |
2021-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
|
JP2022514315A
(ja)
|
2018-12-20 |
2022-02-10 |
ノバルティス アーゲー |
３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
|
|
KR20210107730A
(ko)
|
2018-12-21 |
2021-09-01 |
노파르티스 아게 |
골수 형성이상 증후군의 치료 또는 예방에서의 il-1 베타 항체의 용도
|
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
JP7737143B2
(ja)
|
2018-12-21 |
2025-09-10 |
エイム・イムノテック・インコーポレイテッド |
がん治療のための組成物および方法
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
KR20210109564A
(ko)
|
2018-12-21 |
2021-09-06 |
옹쎄오 |
신규의 컨쥬게이티드 핵산 분자 및 이의 용도
|
|
AU2019409139A1
(en)
|
2018-12-21 |
2021-06-03 |
Novartis Ag |
Use of IL-1β binding antibodies
|
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
|
US20220089541A1
(en)
|
2019-01-25 |
2022-03-24 |
Exelixis, Inc. |
Compounds for the Treatment of Kinase-Dependent Disorders
|
|
EP3918332B1
(en)
|
2019-01-30 |
2025-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
|
|
WO2020160365A1
(en)
|
2019-02-01 |
2020-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Belantamab mafodotin in combination with pembrolizumab for treating cancer
|
|
WO2020161083A1
(en)
|
2019-02-04 |
2020-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
WO2020165370A1
(en)
|
2019-02-13 |
2020-08-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113811549A
(zh)
|
2019-02-21 |
2021-12-17 |
Xencor股份有限公司 |
非靶向和靶向性il-10 fc融合蛋白
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
KR20210141621A
(ko)
|
2019-03-22 |
2021-11-23 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
|
|
CN109929037B
(zh)
*
|
2019-04-01 |
2023-03-17 |
华博生物医药技术（上海）有限公司 |
针对程序性死亡配体的结合物及其应用
|
|
WO2020216379A1
(en)
*
|
2019-04-26 |
2020-10-29 |
I-Mab |
Human pd-l1 antibodies
|
|
WO2020221796A1
(en)
|
2019-04-30 |
2020-11-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
CN114302875A
(zh)
|
2019-05-16 |
2022-04-08 |
斯汀塞拉股份有限公司 |
氧代吖啶基乙酸衍生物及使用方法
|
|
JP2022533194A
(ja)
|
2019-05-16 |
2022-07-21 |
スティングセラ インコーポレイテッド |
ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
|
|
ES3008963T3
(en)
|
2019-06-03 |
2025-03-25 |
Exelixis Inc |
Crystalline salt forms of a kinase inhibitor
|
|
AR119069A1
(es)
|
2019-06-04 |
2021-11-24 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de quinasas
|
|
EP3990494A1
(en)
|
2019-06-26 |
2022-05-04 |
GlaxoSmithKline Intellectual Property Development Limited |
Il1rap binding proteins
|
|
JP2022539208A
(ja)
|
2019-07-03 |
2022-09-07 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
|
|
GB201910138D0
(en)
|
2019-07-15 |
2019-08-28 |
Capella Bioscience Ltd |
Anti-pd-l1 antibodies
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
CN112300279A
(zh)
*
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
MX2022002315A
(es)
|
2019-08-30 |
2022-03-25 |
Agenus Inc |
Anticuerpos anti-cd96 y sus metodos de uso.
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
MX2022003523A
(es)
|
2019-09-27 |
2022-04-25 |
Glaxosmithkline Ip Dev Ltd |
Proteinas de union a antigenos.
|
|
TWI832013B
(zh)
*
|
2019-09-30 |
2024-02-11 |
大陸商諾納生物（蘇州）有限公司 |
一種抗pd-l1抗原結合蛋白及其應用
|
|
US20220354811A1
(en)
|
2019-10-03 |
2022-11-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
|
WO2021076574A2
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
|
CN114786682B
(zh)
|
2019-10-14 |
2024-07-16 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
|
US12491255B2
(en)
|
2019-10-14 |
2025-12-09 |
Aro Biotherapeutics Company |
EPCAM binding fibronectin type III domains
|
|
EP4045686A1
(en)
|
2019-10-17 |
2022-08-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
|
KR20220103947A
(ko)
|
2019-10-21 |
2022-07-25 |
노파르티스 아게 |
베네토클락스 및 tim-3 억제제를 사용한 조합 요법
|
|
AU2020370832A1
(en)
|
2019-10-21 |
2022-05-19 |
Novartis Ag |
TIM-3 inhibitors and uses thereof
|
|
EP4051286A1
(en)
|
2019-10-29 |
2022-09-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating uveal melanoma
|
|
US20230000864A1
(en)
|
2019-11-22 |
2023-01-05 |
Sumitomo Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
WO2021113307A2
(en)
*
|
2019-12-02 |
2021-06-10 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against pd-l1 and methods of use thereof
|
|
WO2021119753A1
(en)
|
2019-12-18 |
2021-06-24 |
Ctxt Pty Limited |
Compounds
|
|
EP4076508A1
(en)
|
2019-12-19 |
2022-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions to treat cancers
|
|
US11760802B2
(en)
|
2019-12-19 |
2023-09-19 |
Ngm Biopharmaceuticals, Inc. |
ILT3-binding agents and methods of use thereof
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
CN111378042A
(zh)
*
|
2020-01-15 |
2020-07-07 |
哈尔滨医科大学 |
一种切伦科夫荧光成像探针及其制备方法与应用
|
|
AU2021207348A1
(en)
|
2020-01-17 |
2022-08-11 |
Novartis Ag |
Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
US20230076415A1
(en)
|
2020-01-17 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
US20230090446A1
(en)
|
2020-01-28 |
2023-03-23 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
CN115038466A
(zh)
|
2020-01-28 |
2022-09-09 |
葛兰素史密斯克莱知识产权发展有限公司 |
联合治疗及其用途和方法
|
|
WO2021156360A1
(en)
|
2020-02-05 |
2021-08-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
|
EP4110955A1
(en)
|
2020-02-28 |
2023-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, prognosing and managing treatment of breast cancer
|
|
EP4110830A4
(en)
|
2020-02-28 |
2024-09-11 |
Tallac Therapeutics, Inc. |
TRANSGLUTAMINASE-MEDIATED CONJUGATION
|
|
CN115461362A
(zh)
|
2020-04-14 |
2022-12-09 |
葛兰素史密斯克莱知识产权发展有限公司 |
基于ICOS抗体和PD-L1抗体TGF-β受体融合蛋白的癌症组合疗法
|
|
EP4143229B1
(en)
|
2020-05-01 |
2025-07-30 |
NGM Biopharmaceuticals, Inc. |
Ilt-binding agents and methods of use thereof
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
|
CN116813777A
(zh)
|
2020-06-22 |
2023-09-29 |
恩格姆生物制药公司 |
Lair-1结合剂及其使用方法
|
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
|
|
EP4189395A1
(en)
|
2020-07-28 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for preventing and treating a cancer
|
|
AU2021318134A1
(en)
|
2020-07-31 |
2023-03-02 |
Exelixis, Inc. |
Combinations for the treatment of cancer
|
|
CN116134027B
(zh)
|
2020-08-03 |
2025-01-24 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
US20230314440A1
(en)
|
2020-08-21 |
2023-10-05 |
Exelixis, Inc. |
Method of treating cancer
|
|
CA3187272A1
(en)
|
2020-10-08 |
2022-04-14 |
Thorsten Ross |
Trispecific binders
|
|
WO2022081886A1
(en)
*
|
2020-10-14 |
2022-04-21 |
Xencor, Inc. |
Bispecific antibodies that bind pd-l1 and cd28
|
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
|
CA3199095A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
US20230416838A1
(en)
|
2020-11-16 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
EP4244391A1
(en)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
PH12023552345A1
(en)
|
2021-03-02 |
2024-04-22 |
Glaxosmithkline Ip Dev Ltd |
Substituted pyridines as dnmt1 inhibitors
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
WO2022194908A1
(en)
|
2021-03-17 |
2022-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
JP2024511831A
(ja)
|
2021-03-31 |
2024-03-15 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質およびそれらの組み合わせ
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022221227A1
(en)
|
2021-04-13 |
2022-10-20 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
JP2024517610A
(ja)
|
2021-04-14 |
2024-04-23 |
アロ・バイオセラピューティクス・カンパニー |
Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
|
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
US12239710B2
(en)
|
2021-04-14 |
2025-03-04 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
EP4326903A1
(en)
|
2021-04-23 |
2024-02-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
|
WO2022243378A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
IL308154A
(en)
|
2021-07-30 |
2023-12-01 |
Affimed Gmbh |
Double structure antibodies
|
|
US20240426823A1
(en)
|
2021-11-03 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
|
WO2023111203A1
(en)
|
2021-12-16 |
2023-06-22 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
|
EP4452257A1
(en)
|
2021-12-21 |
2024-10-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
US20250368606A1
(en)
|
2021-12-22 |
2025-12-04 |
Exelixis, Inc. |
Crystalline forms and salt forms of a kinase inhibitor
|
|
WO2023164510A1
(en)
|
2022-02-23 |
2023-08-31 |
Xencor, Inc. |
Anti-cd28 x anti-psma antibodies
|
|
WO2023173091A1
(en)
|
2022-03-11 |
2023-09-14 |
Ngm Biopharmaceuticals, Inc. |
Osteoclast-associated ig-like receptor (oscar) and methods of use thereof
|
|
EP4493189A1
(en)
|
2022-03-14 |
2025-01-22 |
Laekna Limited |
Combination treatment for cancer
|
|
WO2023194656A1
(en)
|
2022-04-08 |
2023-10-12 |
Tilt Biotherapeutics Oy |
Monoclonal pd-l1 antibodies
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
US20250340641A1
(en)
|
2022-05-18 |
2025-11-06 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
|
WO2024056716A1
(en)
|
2022-09-14 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
|
EP4605000A1
(en)
|
2022-10-21 |
2025-08-27 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
|
EP4658310A1
(en)
|
2023-01-30 |
2025-12-10 |
Kymab Limited |
Antibodies
|
|
WO2024200571A1
(en)
|
2023-03-28 |
2024-10-03 |
Institut National de la Santé et de la Recherche Médicale |
Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024228167A1
(en)
|
2023-05-03 |
2024-11-07 |
Iox Therapeutics Inc. |
Inkt cell modulator liposomal compositions and methods of use
|
|
WO2024231384A1
(en)
|
2023-05-10 |
2024-11-14 |
Institut National de la Santé et de la Recherche Médicale |
Compositions for treating senescence related disease
|
|
WO2024245951A1
(en)
|
2023-05-26 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
|
|
WO2024256635A1
(en)
|
2023-06-15 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Dpm1 inhibitor for treating cancer
|
|
WO2025049908A1
(en)
*
|
2023-09-01 |
2025-03-06 |
Normunity, Inc. |
Anti-pla2g10 antibodies and methods of use
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025078632A1
(en)
|
2023-10-12 |
2025-04-17 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from cancer
|
|
WO2025132479A1
(en)
|
2023-12-18 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Flt3 inhibitor for modulating macrophages polarization
|
|
WO2025132770A1
(en)
|
2023-12-22 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Affitins for the treatment of cancer
|
|
WO2025210123A1
(en)
|
2024-04-03 |
2025-10-09 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating cancers
|
|
WO2025219330A1
(en)
|
2024-04-15 |
2025-10-23 |
Institut National de la Santé et de la Recherche Médicale |
Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
|
|
WO2025228998A1
(en)
|
2024-04-30 |
2025-11-06 |
Institut National de la Santé et de la Recherche Médicale |
Use of hdac4 inhibitors for the treatment of melanoma
|
|
WO2025247829A1
(en)
|
2024-05-27 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating prostate cancer
|